Adipocyte-derived players in hematologic tumors: useful novel targets?

Bibliography

• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24
   PubMed Web of Science ®Google Scholar
• Krishnan C, George TI, Arber DA. Bone marrow metastases: a survey of nonhematologic metastases with immunohistochemical study of metastatic carcinomas. Appl Immunohistochem Mol Morphol 2007;15:1-7
   PubMedGoogle Scholar
• Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer metastasis Rev 2014;33(2-3):527-43
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Rachner TD, Coleman RE, Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2014;2:500-12
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40
   PubMed Web of Science ®Google Scholar
• Johrer K, Hofbauer SW, Zelle-Rieser C, et al. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention? Expert Opin Biol Ther 2012;12:425-41
   PubMed Web of Science ®Google Scholar
• Johrer K, Pleyer L, Olivier A, et al. Tumour-immune cell interactions modulated by chemokines. Expert Opin Biol Ther 2008;8:269-90
   PubMed Web of Science ®Google Scholar
• Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 2014;122:91-128
   PubMed Web of Science ®Google Scholar
• Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008;453:783-7
   PubMed Web of Science ®Google Scholar
• Vande Berg BC, Lecouvet FE, Michaux L, et al. Magnetic resonance imaging of the bone marrow in hematological malignancies. Eur Radiol 1998;8:1335-44
   PubMed Web of Science ®Google Scholar
• Dixit VD. Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol 2008;84:882-92
   PubMedGoogle Scholar
• Yang H, Youm YH, Vandanmagsar B, et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol 2010;185:1836-45
   PubMed Web of Science ®Google Scholar
• Hefetz-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther 2013;138:197-210
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. Eng J Med 2003;348:1625-38
   PubMed Web of Science ®Google Scholar
• Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010;61:301-16
   PubMed Web of Science ®Google Scholar
• Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 2010;15:1083-101
   PubMed Web of Science ®Google Scholar
• Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 2011:47:1606-15
   Google Scholar
• Weiss L, Melchardt T, Habringer S, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol 2014;25:171-6
   PubMed Web of Science ®Google Scholar
• Aplenc R, Zhang MJ, Sung L, et al. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood 2014;123(22):3504-11
   PubMed Web of Science ®Google Scholar
• Vogl DT, Wang T, Perez WS, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011;17:1765-74
   PubMed Web of Science ®Google Scholar
• Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004;84:277-359
   PubMed Web of Science ®Google Scholar
• Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 2009;58:1526-31
   PubMed Web of Science ®Google Scholar
• van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009;360:1500-8
   PubMed Web of Science ®Google Scholar
• Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-25
   PubMed Web of Science ®Google Scholar
• Cao Q, Hersl J, La H, et al. A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer. BMC Cancer 2014;14:126
   PubMed Web of Science ®Google Scholar
• Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986;111:82-5
   PubMed Web of Science ®Google Scholar
• Tsoli M, Moore M, Burg D, et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res 2012;72:4372-82
   PubMed Web of Science ®Google Scholar
• Vijgen G, van Marken Lichtenbelt W. Brown adipose tissue: clinical impact of a re-discovered thermogenic organ. Front Biosci (Elite Ed) 2013;5:823-33
   PubMedGoogle Scholar
• Tavassoli M. Marrow adipose cells. Histochemical identification of labile and stable components. Arch Pathol Lab Med 1976;100:16-18
   PubMed Web of Science ®Google Scholar
• Justesen J, Stenderup K, Ebbesen EN, et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001;2:165-71
   PubMed Web of Science ®Google Scholar
• Bredella MA, Fazeli PK, Miller KK, et al. Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab 2009;94:2129-36
   PubMed Web of Science ®Google Scholar
• Devlin MJ, Cloutier AM, Thomas NA, et al. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 2010;25:2078-88
   PubMed Web of Science ®Google Scholar
• Cawthorn WP, Scheller EL, Learman BS, et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab 2014;20(2):368-75
   PubMed Web of Science ®Google Scholar
• Krings A, Rahman S, Huang S, et al. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 2012;50:546-52
   Google Scholar
• Calo E, Quintero-Estades JA, Danielian PS, et al. Rb regulates fate choice and lineage commitment in vivo. Nature 2010;466:1110-14
   PubMed Web of Science ®Google Scholar
• Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004;3:379-89
   PubMed Web of Science ®Google Scholar
• Takeshita S, Fumoto T, Naoe Y, Ikeda K. Age-related marrow adipogenesis is linked to increased expression of RANKL. J Biol Chem 2014;289(24):16699-710
   PubMed Web of Science ®Google Scholar
• Naveiras O, Nardi V, Wenzel PL, et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009;460:259-63
   PubMed Web of Science ®Google Scholar
• Bryon PA, Gentilhomme O, Fiere D. [Histomorphometric analysis of bone-marrow adipose density and heterogeneity in myeloid aplasia and dysplasia (author’s transl)]. Pathologie-biologie 1979;27:209-13
   PubMed Web of Science ®Google Scholar
• Takaku T, Malide D, Chen J, et al. Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood 2010;116:e41-55
   Google Scholar
• Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med 2012;272:317-29
   PubMed Web of Science ®Google Scholar
• Zhao E, Xu H, Wang L, et al. Bone marrow and the control of immunity. Cell Mol Immunol 2012;9:11-19
   PubMed Web of Science ®Google Scholar
• Trubowitz S, Bathija A. Cell size and plamitate-1-14c turnover of rabbit marrow fat. Blood 1977;49:599-605
   PubMed Web of Science ®Google Scholar
• Griffith JF, Yeung DK, Ahuja AT, et al. A study of bone marrow and subcutaneous fatty acid composition in subjects of varying bone mineral density. Bone 2009;44:1092-6
   PubMed Web of Science ®Google Scholar
• Liu LF, Shen WJ, Ueno M, et al. Characterization of age-related gene expression profiling in bone marrow and epididymal adipocytes. BMC Genomics 2011;12:212
   PubMed Web of Science ®Google Scholar
• Poloni A, Maurizi G, Serrani F, et al. Molecular and functional characterization of human bone marrow adipocytes. Exp Hematol 2013;41:558-66. e552
   PubMed Web of Science ®Google Scholar
• Alvarez-Llamas G, Szalowska E, de Vries MP, et al. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics 2007;6:589-600
   PubMed Web of Science ®Google Scholar
• Lehr S, Hartwig S, Lamers D, et al. Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 2012;11:M111.010504
   PubMed Web of Science ®Google Scholar
• Zhong J, Krawczyk SA, Chaerkady R, et al. Temporal profiling of the secretome during adipogenesis in humans. J Proteome Res 2010;9:5228-38
   PubMed Web of Science ®Google Scholar
• Kabir SM, Lee ES, Son DS. Chemokine network during adipogenesis in 3T3-L1 cells: differential response between growth and proinflammatory factor in preadipocytes vs. adipocytes. Adipocyte 2014;3:97-106
   PubMedGoogle Scholar
• Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-45
   PubMed Web of Science ®Google Scholar
• DiMascio L, Voermans C, Uqoezwa M, et al. Identification of adiponectin as a novel hemopoietic stem cell growth factor. J Immunol 2007;178:3511-20
   PubMed Web of Science ®Google Scholar
• Lee HW, Kim SY, Kim AY, et al. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells 2009;27:2254-62
   Google Scholar
• Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520-6
   PubMed Web of Science ®Google Scholar
• Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300
   PubMed Web of Science ®Google Scholar
• Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-13
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008;409:623-33
   PubMed Web of Science ®Google Scholar
• Asterholm IW, Scherer PE. Enhanced metabolic flexibility associated with elevated adiponectin levels. The American journal of pathology 2010;176:1364-76
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32
   PubMed Web of Science ®Google Scholar
• Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008;70:537-56
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte Det al. Central nervous system control of food intake. Nature 2000;404:661-71
   PubMed Web of Science ®Google Scholar
• Bennett BD, Solar GP, Yuan JQ, et al. A role for leptin and its cognate receptor in hematopoiesis. Current biology : CB 1996;6:1170-80
   PubMed Web of Science ®Google Scholar
• Lam QL, Wang S, Ko OK, et al. Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1. Proc Natl Acad Sci USA 2010;107:13812-17
   PubMed Web of Science ®Google Scholar
• Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol 2007;4:1-13
   PubMed Web of Science ®Google Scholar
• De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007;26:241-55
   PubMed Web of Science ®Google Scholar
• Lord GM, Matarese G, Howard JK, et al. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukoc Biol 2002;72:330-8
   PubMed Web of Science ®Google Scholar
• Dixit VD, Yang H, Sun Y, et al. Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007;117:2778-90
   PubMed Web of Science ®Google Scholar
• Roszer T, Jozsa T, Kiss-Toth ED, et al. Leptin receptor deficient diabetic (db/db) mice are compromised in postnatal bone regeneration. Cell Tissue Res 2014;356:195-206
   PubMed Web of Science ®Google Scholar
• Turner RT, Kalra SP, Wong CP, et al. Peripheral leptin regulates bone formation. J Bone Miner Res 2013;28:22-34
   PubMed Web of Science ®Google Scholar
• Ataie-Kachoie P, Pourgholami MH, Richardson DR, Morris DL. Gene of the month: interleukin 6 (IL-6). J Clin Pathol 2014;10.1136/jclinpath-2014-202493
   Web of Science ®Google Scholar
• Aarden LA. Hybridoma growth factor. Ann N Y Acad Sci 1989;557:192-8. discussion 198-199
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8
   PubMed Web of Science ®Google Scholar
• Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 1985;2005:98-1154-62
   Google Scholar
• Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2
   PubMed Web of Science ®Google Scholar
• Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4
   PubMed Web of Science ®Google Scholar
• Pujol-Borrell R, Todd I, Doshi M, et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987;326:304-6
   PubMed Web of Science ®Google Scholar
• Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-9
   PubMed Web of Science ®Google Scholar
• Ara T, Tokoyoda K, Sugiyama T, et al. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003;19:257-67
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25:977-88
   PubMed Web of Science ®Google Scholar
• Hargreaves DC, Hyman PL, Lu TT, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001;194:45-56
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Egawa T, Sugiyama T, et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004;20:707-18
   PubMed Web of Science ®Google Scholar
• Takano T, Li YJ, Kukita A, et al. Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis. Lab Invest 2014;94:286-96
   PubMed Web of Science ®Google Scholar
• Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013;218:1376-84
   PubMed Web of Science ®Google Scholar
• Roca H, Varsos ZS, Sud S, et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009;284:34342-54
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808
   PubMed Web of Science ®Google Scholar
• Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005;280:16163-9
   PubMed Web of Science ®Google Scholar
• Arendt LM, McCready J, Keller PJ, et al. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 2013;73:6080-93
   PubMed Web of Science ®Google Scholar
• Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006;94:1221-5
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 2009;20:193-9
   PubMed Web of Science ®Google Scholar
• Hofmann JN, Liao LM, Pollak MN, et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 2012;120:4418-20
   PubMed Web of Science ®Google Scholar
• Caers J, Deleu S, Belaid Z, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia 2007;21:1580-4
   PubMed Web of Science ®Google Scholar
• Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-66
   PubMed Web of Science ®Google Scholar
• Korner A, Pazaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041-8
   PubMed Web of Science ®Google Scholar
• Fowler JA, Lwin ST, Drake MT, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011;118:5872-82
   PubMed Web of Science ®Google Scholar
• Medina EA, Oberheu K, Polusani SR, et al. PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells. Leukemia 2014;10.1038/leu.2014.112
   PubMed Web of Science ®Google Scholar
• Gado K, Domjan G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000;24:195-209
   PubMed Web of Science ®Google Scholar
• Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 2012;120:4929-37
   PubMed Web of Science ®Google Scholar
• Jourdan M, Tarte K, Legouffe E, et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999;10:65-70
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27
   PubMed Web of Science ®Google Scholar
• Arendt BK, Velazquez-Dones A, Tschumper RC, et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002;16:2142-7
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Asosingh K, Vanderkerken K, et al. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013;27:702-10
   PubMed Web of Science ®Google Scholar
• Johrer K, Janke K, Krugmann J, et al. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004;10:1901-10
   PubMed Web of Science ®Google Scholar
• Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002;1:539-44
   PubMed Web of Science ®Google Scholar
• Sison EA, McIntyre E, Magoon D, Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Molecular cancer research : MCR 2013;11:1004-16
   PubMed Web of Science ®Google Scholar
• Pramanik R, Sheng X, Ichihara B, et al. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. Leuk Res 2013;37:503-9
   PubMed Web of Science ®Google Scholar
• Behan JW, Yun JP, Proektor MP, et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009;69:7867-74
   PubMed Web of Science ®Google Scholar
• Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25:1182-8
   PubMed Web of Science ®Google Scholar
• Decker S, Finter J, Forde AJ, et al. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther 2014;13:1231-45
   PubMed Web of Science ®Google Scholar
• Johrer K, Obkircher M, Neureiter D, et al. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target. J Mol Med 2012;90:681-93
   PubMed Web of Science ®Google Scholar
• Ehsanipour EA, Sheng X, Behan JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res 2013;73:2998-3006
   PubMed Web of Science ®Google Scholar
• Battula VL, Chen Y, Cabreira Mda G, et al. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood 2013;122:357-66
   PubMed Web of Science ®Google Scholar
• Ruan J, Trotter TN, Nan L, et al. Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone 2013;57:10-17
   PubMed Web of Science ®Google Scholar
• Chen Q, Yuan Y, Chen T. Morphology, differentiation and adhesion molecule expression changes of bone marrow mesenchymal stem cells from acute myeloid leukemia patients. Molecular medicine reports 2014;9:293-8
   PubMed Web of Science ®Google Scholar
• Herroon MK, Rajagurubandara E, Hardaway AL, et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 2013;4:2108-23
   PubMedGoogle Scholar
• Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503
   PubMed Web of Science ®Google Scholar
• Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011;333:233-8
   PubMed Web of Science ®Google Scholar
• Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 2011;71:2455-65
   PubMed Web of Science ®Google Scholar
• Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013;1831:1533-41
   PubMed Web of Science ®Google Scholar
• Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13:27-9
   PubMed Web of Science ®Google Scholar
• Louie SM, Roberts LS, Mulvihill MM, et al. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim Biophys Acta 2013;1831:1566-72
   PubMed Web of Science ®Google Scholar
• Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008;47:348-80
   PubMed Web of Science ®Google Scholar
• Holley RW, Baldwin JH, Kiernan JA. Control of growth of a tumor cell by linoleic acid. Proc Natl Acad Sci USA 1974;71:3976-8
   PubMed Web of Science ®Google Scholar
• Butler M, Huzel N, Barnabe N. Unsaturated fatty acids enhance cell yields and perturb the energy metabolism of an antibody-secreting hybridoma. Biochem J 1997;322(Pt 2):615-23
   PubMedGoogle Scholar
• Girao LA, Ruck AC, Cantrill RC, Davidson BC. The effect of C18 fatty acids on cancer cells in culture. Anticancer Res 1986;6:241-4
   PubMed Web of Science ®Google Scholar
• Sravan Kumar G, Das UN. Cytotoxic action of alpha-linolenic and eicosapentaenoic acids on myeloma cells in vitro. Prostaglandins Leukot Essent Fatty Acids 1997;56:285-93
   PubMed Web of Science ®Google Scholar
• Finstad HS, Myhrstad MC, Heimli H, et al. Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids. Leukemia 1998;12:921-9
   PubMed Web of Science ®Google Scholar
• Wirtitsch M, Roth E, Bachleitner-Hofmann T, et al. Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells. Oncol Res 2009;18:83-94
   PubMed Web of Science ®Google Scholar
• Iversen PO, Sorensen DR, Tronstad KJ, et al. A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clinical Cancer Res 2006;12:3525-31
   PubMed Web of Science ®Google Scholar
• Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism 2014;63:895-902
   PubMed Web of Science ®Google Scholar
• Baumann J, Sevinsky C, Conklin DS. Lipid biology of breast cancer. Biochim Biophys Acta 2013;1831:1509-17
   PubMed Web of Science ®Google Scholar
• Nomura DK, Cravatt BF. Lipid metabolism in cancer. Biochim Biophys Acta 2013;1831:1497-8
   PubMed Web of Science ®Google Scholar
• Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013;52:585-9
   PubMed Web of Science ®Google Scholar
• Wang WQ, Zhao XY, Wang HY, Liang Y. Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. Journal of Zhejiang University Science B 2008;9:441-7
   PubMed Web of Science ®Google Scholar
• Gao F, Chattopadhyay A, Navab M, et al. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1alpha in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther 2012;342:255-62
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65
   PubMed Web of Science ®Google Scholar
• Puig T, Aguilar H, Cufi S, et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res 2011;13:R131
   PubMed Web of Science ®Google Scholar
• Turrado C, Puig T, Garcia-Carceles J, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem 2012;55:5013-23
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005;8:311-21
   PubMed Web of Science ®Google Scholar
• Bauer DE, Hatzivassiliou G, Zhao F, et al. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005;24:6314-22
   PubMed Web of Science ®Google Scholar
• Eberhard Y, Gronda M, Hurren R, et al. Inhibition of SREBP1 sensitizes cells to death ligands. Oncotarget 2011;2:186-96
   Google Scholar
• Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 2007;68:72-82
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Joshi A, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010;17:348-61
   PubMed Web of Science ®Google Scholar
• Yang Y, Morin PJ, Han WF, et al. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 2003;282:132-7
   PubMed Web of Science ®Google Scholar
• Quan HY, Kim do Y, Kim SJ, et al. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol 2013;85:1330-40
   PubMed Web of Science ®Google Scholar
• Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009;14:885-90
   PubMed Web of Science ®Google Scholar
• Park SY, Kim HJ, Kim KR, et al. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment. Toxicol Appl Pharmacol 2014;275:152-62
   PubMed Web of Science ®Google Scholar
• Li J, Zhao S, Zhou X, et al. Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxel. PLoS One 2013;8:e74623
   Google Scholar
• Samudio I, Harmancey R, Fiegl M, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010;120:142-56
   PubMed Web of Science ®Google Scholar
• Gimble JM, Nuttall ME. The relationship between adipose tissue and bone metabolism. Clin Biochem 2012;45:874-9
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007;148:903-11
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113:4341-51
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Zboralski D, Maasch C, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 2014;123:1032-9
   PubMed Web of Science ®Google Scholar
• Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67:9417-24
   PubMed Web of Science ®Google Scholar
• Ma Y, Mattarollo SR, Adjemian S, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014;74:436-45
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clinical Cancer Res 2010;16:6139-49
   PubMed Web of Science ®Google Scholar
• Charbonneau B, O’Connor HM, Wang AH, et al. Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma. J Nutr 2013;143:672-81
   PubMed Web of Science ®Google Scholar
• Yang B, Ren XL, Fu YQ, et al. Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies. BMC Cancer 2014;14:105
   PubMed Web of Science ®Google Scholar
• Ahmadian M, Suh JM, Hah N, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 2013;19:557-66
   PubMed Web of Science ®Google Scholar